gba
Eisai: Fycompa decision ‘deeply regrettable’
November 11, 2014Research and Development, Sales and Marketing Eisai, Fycompa, Germany, epilepsy, gba, perampanel
Eisai has lashed out at a major German health assessment body, calling its stance on first-in-class epilepsy treatment Fycompa ‘deeply …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
